✦ LIBER ✦

396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors

✍ Scribed by de Jonge, M.; Sahebjam, S.; Mathijssen, R.H.; Razak, A.; van der Biessen, D.; Pronk, L.C.; Schnell, D.; Siu, L.L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I, first-in-human dose-escalatio

✍ Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 232 KB

Phase 1 dose-escalation study of oral ty

✍ J.C. Soria; C. Massard; N. Magné; Th. Bader; C.D. Mansfield; J.Y. Blay; B.N. Bui 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 288 KB

Phase I study of barasertib (AZD1152), a

✍ Gary K. Schwartz,Richard D. Carvajal,Rachel Midgley… 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 389 KB

Phase I, dose escalation and pharmacokin

✍ Noboru Yamamoto; Tomohide Tamura; Nobuyuki Yamamoto; Kazuhiko Yamada; Yasuhide Y 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 436 KB

Phase I dose escalation study of MK-0457

✍ Anne M. Traynor; Maureen Hewitt; Glenn Liu; Keith T. Flaherty; Jason Clark; Stev 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 252 KB

Phase I study of caelyx and carboplatin

✍ A. Braud; A. Goncalves; D. Genre; G. Gravis; F. Viret; J. Camerlo; M. Cappiello; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 189 KB